Boothbay Fund Management’s Ionis Pharmaceuticals IONS Stock Holding History

Boothbay Fund Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.3M	Buy	+92,100	New	+$6.93M	0.1%	229
2023 Q2	–	Sell	-6,500	Closed	-$232K	–	2027
2023 Q1	$232K	Buy	6,500 +400	+7%	+$15K	﹤0.01%	1654
2022 Q4	$230K	Buy	+6,100	New	+$257K	0.01%	1537
2019 Q4	–	Sell	-262	Closed	-$1.57M	–	910
2019 Q3	$1.57M	Buy	+262	New	+$17.1K	0.14%	194
2018 Q4	–	Sell	-288	Closed	-$1.49M	–	760
2018 Q3	$1.49M	Buy	+288	New	+$13.5K	0.15%	134
2016 Q4	–	Sell	-16,000	Closed	-$586K	–	844
2016 Q3	$586K	Hold	16,000	–	–	0.13%	173
2016 Q2	$373K	Buy	16,000 +7,700	+93%	+$248K	0.14%	193
2016 Q1	$336K	Buy	+8,300	New	+$337K	0.09%	338

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Boothbay Fund Management's IONS Position: Q2 2026 in Review

Boothbay Fund Management reduced its Ionis Pharmaceuticals (IONS) stake by 85% in Q2 2026, selling an estimated $4.87M and leaving 11,808 shares worth $936K. The position accounts for 0.01% of the portfolio, ranked #1136.

Boothbay Fund Management first reported a position in IONS in Q3 2025 and has held it in 4 quarters since. The position peaked at $10.7M in Q3 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Boothbay Fund Management held 11,808 shares of Ionis Pharmaceuticals worth $936K as of Q2 2026.
Boothbay Fund Management sold 64,763 Ionis Pharmaceuticals shares in Q2 2026, an estimated $4.87M.
Ionis Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1136 holding.
Boothbay Fund Management first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
Boothbay Fund Management's Ionis Pharmaceuticals position peaked at $10.7M in Q3 2025.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.